Flow compensation is based on the principle of even echo rephasing and a function of specific pulse sequences, wherein the application of strategic gradient pulses can compensate for the objectionable spin phase effects of flow motion. Gradient moment nulling of the first order of flow is another adjustment for the reduction of flow artifacts.
Gradient field changes can be configured in such a way that during an echo the magnetization signal vectors for all pixels have zero phase angle independent of velocities, accelerations etc. of the measured tissue. The simplest velocity-compensated pulse sequence is the symmetrical second echo of a spin echo pulse sequence.
Strategic gradient pulses are integrated in special sequences (e.g. CRISP, Complex Rephasing Integrated with Surface Probes) and for the most sequences flow compensation is an optional parameter.

Quick Overview

Ghosting artifacts are in the most cases caused by movements (e.g., respiratory motion, bowel motion, arterial pulsations, swallowing, and heartbeat) and appear in the phase encoding direction.

Ghosting artifacts can be reduced by respiratory and cardiac triggering, the use of breath holding pulse sequences, flow compensation or presaturation pulses, depending on their origin. To reduce bowel motion also pharmaceuticals, such as glucagon or scopolamine are useful. This will decrease artifacts from both peristalsis and breathing.

See also Motion Artifact, Phase Encoded Motion Artifact, Cardiac Motion Artifact, and Artifact Reduction - Motion.

(GMR) The application of strategic gradient pulses can compensate the objectionable spin phase effects of flow motion. That means the reducing of flow effects, e.g. gradient moment nulling of the first order of flow. The simplest velocity-compensated pulse sequence is the symmetrical second echo of a spin echo pulse sequence.
Gradient field changes can be configured in such a way that during an echo the magnetization signal vectors for all pixels have zero phase angle independent of velocities, accelerations etc. of the measured tissue. E.g. the adjustment to zero at the time TE of the net moments of the amplitude of the waveform of the magnetic field gradients with time. The zeroth moment is the area under the curve, the first moment is the 'center of gravity' etc. The aim is to minimize the phase shifts acquired by the transverse magnetization of excited nuclei moving along the gradients (including the effect of refocusing RF pulses), particularly for the reduction of image artifacts due to motion.
Also called Flow Compensation (FC), Motion Artifact Suppression Technique (MAST), Flow motion compression (STILL), Gradient Rephasing (GR), Shimadzu Motion Artifact Reduction Technique (SMART).

Liver imaging can be performed with sonography, computed tomography (CT) and magnetic resonance imaging (MRI). Ultrasound is, caused by the easy access, still the first-line imaging method of choice; CT and MRI are applied whenever ultrasound imaging yields vague results. Indications are the characterization of metastases and primary liver tumors e.g., benign lesions such as focal nodular hyperplasia (FNH), adenoma, hemangioma and malignant lesions (cancer) such as hepatocellular carcinomas (HCC). The decision, which medical imaging modality is more suitable, MRI or CT, is dependent on the different factors. CT is less costly and more widely available; modern multislice scanners provide high spatial resolution and short scan times but has the disadvantage of radiation exposure.
With the introduction of high performance MR systems and advanced sequences the image quality of MRI for the liver has gained substantially. Fast spin echo or single shot techniques, often combined with fat suppression, are the most common T2 weighted sequences used in liver MRI procedures. Spoiled gradient echo sequences are used as ideal T1 weighted sequences for evaluating of the liver. The repetition time (TR) can be sufficiently long to acquire enough sections covering the entire liver in one pass, and to provide good signal to noise. The TE should be the shortest in phase echo time (TE), which provides strong T1 weighting, minimizes magnetic susceptibility effects, and permits acquisition within one breath hold to cover the whole liver. A flip angle of 80° provides good T1 weighting and less of power deposition and tissue saturation than a larger flip angle that would provide comparable T1 weighting.
Liver MRI is very dependent on the administration of contrast agents, especially when detection and characterization of focal lesions are the issues. Liver MRI combined with MRCP is useful to evaluate patients with hepatic and biliary disease.
Gadolinium chelates are typical non-specific extracellular agents diffusing rapidly to the extravascular space of tissues being cleared by glomerular filtration at the kidney. These characteristics are somewhat problematic when a large organ with a huge interstitial space like the liver is imaged. These agents provide a small temporal imaging window (seconds), after which they begin to diffuse to the interstitial space not only of healthy liver cells but also of lesions, reducing the contrast gradient necessary for easy lesion detection. Dynamic MRI with multiple phases after i.v. contrast media (Gd chelates), with arterial, portal and late phase images (similar to CT) provides additional information.
An additional advantage of MRI is the availability of liver-specific contrast agents (see also Hepatobiliary Contrast Agents). Gd-EOB-DTPA (gadoxetate disodium, Gadolinium ethoxybenzyl dimeglumine, EOVIST Injection, brand name in other countries is Primovist) is a gadolinium-based MRI contrast agent approved by the FDA for the detection and characterization of known or suspected focal liver lesions.
Gd-EOB-DTPA provides dynamic phases after intravenous injection, similarly to non-specific gadolinium chelates, and distributes into the hepatocytes and bile ducts during the hepatobiliary phase. It has up to 50% hepatobiliary excretion in the normal liver.
Since ferumoxides are not eliminated by the kidney, they possess long plasmatic half-lives, allowing circulation for several minutes in the vascular space. The uptake process is dependent on the total size of the particle being quicker for larger particles with a size of the range of 150 nm (called superparamagnetic iron oxide). The smaller ones, possessing a total particle size in the order of 30 nm, are called ultrasmall superparamagnetic iron oxide particles and they suffer a slower uptake by RES cells. Intracellular contrast agents used in liver MRI are primarily targeted to the normal liver parenchyma and not to pathological cells. Currently, iron oxide based MRI contrast agents are not marketed.
Beyond contrast enhanced MRI, the detection of fatty liver disease and iron overload has clinical significance due to the potential for evolution into cirrhosis and hepatocellular carcinoma. Imaging-based liver fat quantification (see also Dixon) provides noninvasively information about fat metabolism; chemical shift imaging or T2*-weighted imaging allow the quantification of hepatic iron concentration.

See also Abdominal Imaging, Primovistâ„¢, Liver Acquisition with Volume Acquisition (LAVA), T1W High Resolution Isotropic Volume Examination (THRIVE) and Bolus Injection.

For Ultrasound Imaging (USI) see Liver Sonography at Medical-Ultrasound-Imaging.com.

The number of data points collected in one, two or all three directions. Normally used for the 2D in plane sampling. The display matrix may be different from the acquisition matrix, although the latter determines the resolution. Measurement time may be saved by not acquiring raw data lines corresponding to high resolution. Not measured rows are filled with zeroes prior to the image calculation. A square image is the result of an interpolation in phase encoding direction. See also Zero Filling.

The chosen matrix size effects scan time, resolution and SNR. Reduced measurement matrixes decrease the scan time and the resolution by increased SNR.